Institute stops trial on Revatio for sickle cell disease

07/29/2009 | Wall Street Journal, The

The National Heart, Lung and Blood Institute halted a study on Revatio, a drug that contains the key ingredient in Viagra, in patients with sickle cell disease because of safety issues. The study indicated a significantly higher risk of serious side effects in patients taking Revatio compared with those on placebo.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care